Key result
In vitro application of VP1-specific dsRNAs and siRNAs completely inhibited Coxsackievirus B3 neurotropic strain Nancy at a non-cytotoxic concentration of 0.3 μmol/L.
Why the study?
Coxsackieviruses cause serious life-threatening diseases, and genetic silencing represents a potential new approach to treat viral infections.
VP1-specific dsRNAs and siRNAs effectively inhibit coxsackievirus B3 at low, non-cytotoxic concentrations in vitro.
Answers are grounded in this paper and cite their sources.
siRNA silencing of CVB3 VP1 merits in vivo testing; leaves open any role in clinical enteroviral disease.
Coxsackieviruses are distributed worldwide and can cause serious diseases threatening human health and even human life. Genetic silencing is considered a new opportunity to treat viral infections. In this study, we produced in vitro dsRNAs and siRNAs specific for two sequences of different length from the VP1 genetic regions of CVB3, and introduced them into HEp-2 cells with Oligofectamine as the transfection agent. We used the neurotropic strain Nancy. The 100% inhibitory concentrations of the applied dsRNAs and siRNAs were 0.3 μmol/L and fell in the range of non-cytotoxic concentration values. The produced VP1-specific dsRNAs and siRNAs were effective at low concentrations, suggesting that the produced RNAs are safe to use and possess excellent potential to treat CVB3 infection.
No takes yet. Share an insight, caveat, or question.
Petrov et al. (2022) studied Coxsackievirus B3 infection. dsRNAs and siRNAs specific for VP1 genetic regions of CVB3 was evaluated on 100% inhibitory concentration. In vitro application of VP1-specific dsRNAs and siRNAs completely inhibited Coxsackievirus B3 neurotropic strain Nancy at a non-cytotoxic concentration of 0.3 μmol/L.
Synapse has enriched 10 related papers. Consider them for comparative context: